Immuno-Designed Molecules SA, of Paris, named Henri Lipmanowicz to its board.

Maxim Pharmaceuticals Inc., of San Diego, added Karl-Hermann Bremeyer as vice president, European operations; Sean Reade as executive director, global regulatory affairs; and Mark Knowles as senior director, biostatistics.

NeoTherapeutics Inc., of Irvine, Calif., added Rosemarie Rosales as assistant director, medical research, of its oncology subsidiary, NeoOncoRx.

Novogen Ltd., of Sydney, Australia, appointed Paul Nestel nonexecutive director.

Prescient NeuroPharma Inc., of Toronto, appointed Jean-Francois Pariseau to its board.